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leiotropic Effects of Statins
cutely Good, But Chronically Bad?*
ainer Schulz, MD, PHD†
ssen, Germany
nhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A
eductase (statins) are powerful lipid-lowering drugs that
ave been proven effective in primary and secondary pre-
ention of coronary artery disease (1). However, ongoing
iscussion persists on whether or not statins exert clinically
elevant protection from cardiovascular disease independent
f their lipid-lowering action (2,3), the so-called pleiotropic
ffects. The pleiotropic effects of statins are related to the
educed formation of isoprenoids, which are responsible for
ost-translational modification of proteins (for review, see
erner et al. [4]). Among those proteins, the reduced
renylation and thus activity of small G-proteins (Ras, Rho)
ppears to be of major importance.
See page 1287
The small G-protein RhoA is involved in myocardial
schemia/reperfusion injury; its pharmacologic blockade re-
uces infarct size in mice after 30 min of coronary artery
cclusion and 24 h of reperfusion (5). RhoA inhibits the
ctivity of protein kinase B (PKB)/Akt, an enzyme that,
ogether with the phosphatidylinositol-3 kinase (PI3K), is
mportant for triggering the cardioprotection achieved by
schemic preconditioning (6,7) and for mediating the reduc-
ion of ischemia/reperfusion injury after treatment with
radykinin (8), insulin, insulin-like growth factor-1, or
rocortin (for review, see Hausenloy and Yellon [9]) (Fig.
). Downstream of PI3K and Akt, endothelial nitric oxide
ynthase 3 (NOS3) activation, mitochondrial adenosine
riphosphate (ATP)-dependent potassium channel activa-
ion, and mitochondrial permeabilty transition pore inhibi-
ion all are involved in mediating the resulting cardiopro-
ective effect (9).
Statins can activate the PI3K/Akt pathway directly by
ncreased translocation of Akt to the sarcolemmal mem-
rane (10) or indirectly by a reduced RhoA activity; Rho A
nhibits PKB/Akt activity (11).
In agreement with its effect on PI3K/Akt, statins reduce
nfarct size after ischemia/reperfusion in mouse (12–15),
at (16–19), dog (20), and pig (21) hearts in vitro (14,16) or
n vivo (12,13,15,17–19,21–23). Infarct size reduction by
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.d
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ermany.tatins is dose-dependent and effective when statin treat-
ent is initiated within three days before ischemia or
ven when started just before reperfusion (14,19). Blockade
f PI3K (14,19,20), NOS3 (13,14,18,19,22), or ATP-
ependent potassium channels (23) abolishes the cardiopro-
ective effect of statins. Increased survival after hypoxia/
eoxygenation by statin treatment also has been observed in
solated human cardiomyocytes (24), indicating that interac-
ion of different cell types is not required for the cardioprotec-
ion to be obtained.
So far, only a single study in rabbits failed to demonstrate
n infarct size reduction by statin treatment; in this study,
abbits fed a cholesterol-rich diet for 16 weeks received
ravastatin (5 mg/kg/day) for 8 weeks before the initiation
f 30 min ischemia followed by reperfusion. Pravastatin had
o significant effect on cholesterol levels, but it restored the
ardioprotection achieved by ischemic preconditioning,
hich was otherwise lost in hearts from hypercholester-
lemic rabbits (25). This finding suggests that the more
cute/subacute direct cardioprotective effect of statins by
odulating protein kinase activity is lost over longer treat-
ent periods but that the potential to potentiate the
ardioprotection achieved by other stimuli remains.
In line with this idea, the study by Mensah et al. (26) in
his issue of the Journal also clearly demonstrates that
torvastatin (20 mg/kg/day), although reducing infarct size
hen given for less than three days before ischemia/
eperfusion, lost its cardioprotective effect when adminis-
ered for one or two weeks before ischemia/reperfusion. The
uthors are the first to associate this finding with an
p-regulation of PTEN (phosphatase and tensin homolog
eleted on chromosome 10), a protein phosphatase known
o inhibit the function of PI3K (27). The expression of
TEN is controlled by peroxisome proliferator-activated
eceptor gamma and—at least in monocytes—peroxisome
roliferator-activated receptor gamma activity is increased
ith chronic statin treatment (28). As a result, although
cute/subacute statin treatment might increase PKB/Akt
ctivity, chronic statin treatment might counteract PKB/Akt
ctivation by increasing PTEN expression. Unfortunately,
either PI3K nor PKB/Akt nor NOS3 phosphorylation
ere assessed in the present study. Also of great importance,
owever, is that acute treatment with 40 mg/kg atorvastatin
to 4 h before ischemia on top of the chronic treatment
estored the reduction in infarct size, suggesting that the
nhibition of PI3K activity and subsequently PKB/Akt
ctivity during chronic statin treatment can be overcome by
cutely increasing PKB/Akt phosphorylation; such in-
reased PKB/Akt phosphorylation occurs acutely after statin
dministration. However, to further prove this idea, studies
ith measurements of PI3K, PKB/Akt, and endothelial
itric oxide synthase phosphorylation during acute statin
reatment on top of chronic therapy are required.
Do all statins act the same? Although an ongoing
iscussion persists on whether or not all statins behave
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April 19, 2005:1292–4 Editorial Commentimilar concerning cardiovascular risk reduction and pleio-
ropic effects (29), all available statins (atorvastatin, cerivas-
atin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, sim-
astatin), when given before ischemia/reperfusion, reduce
nfarct size in animal experiments. Differences might exist
egarding the minimal duration between drug administra-
ion and initiation of ischemia as well as the required drug
oncentration, reflecting the different pharmacologic pro-
les of the drugs.
Is there any evidence that statins reduce the extent of
nfarction clinically? Plaque rupture occurring either spon-
aneously or during coronary interventions causes microin-
arction secondary to coronary microembolization (for re-
iew, see Erbel and Heusch [30] and Heusch et al. [31]).
he extent of microinfarction—as indicated by an increase
n creatine kinase-myocardial band and troponin I—after
oronary interventions is reduced in patients under statin
reatment (32). Although during long-term statin treatment
he plaque volume is reduced (33), thereby reducing the
xtent of coronary microembolization, reduced microinfarc-
ion is observed even when statin treatment is started just
hree (34) to seven days (35) before coronary interventions.
Thus, statins have clearly some acute cholesterol-
ndependent beneficial cardioprotective effects that, how-
ver, might be lost during chronic use. Nevertheless, during
hronic statin treatment, lowering of the lipid load is
ardioprotective. Future clinical studies will have to eluci-
ate whether or not the combination of an acute statin
reatment on top of its chronic use exerts any benefit for the
igure 1. The acute cholesterol-independent cardioprotective effects of
tatins might be lost with chronic treatment by up-regulation of proteins
RhoA, phosphatase and tensin homolog [PTEN]), which inhibit kinases
phosphatidylinositol-3 kinase [PI3K], protein kinase B [PKB]/Akt)
entrally involved in the signal transduction cascade, leading to cardiomy-
cyte survival (for more details, see text). PPAR peroxisome proliferator-
ctivated receptor; NOS3  nitric oxide synthase 3 activation;   acti-
ation;   inhibition.atient.eprint requests and correspondence: Prof. Dr. Rainer Schulz,
nstitut für Pathophysiologie, Zentrum für Innere Medizin, Uni-
ersitätsklinikum Essen, Hufelandstraße 55, 45122 Essen, Germany.
-mail: Rainer_schulz@uni-essen.de.
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